Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jun;61(6):886–890. doi: 10.1038/bjc.1990.198

Detection of P24 protein in human breast cancer: influence of receptor status and oestrogen exposure.

L Seymour 1, W R Bezwoda 1, K Meyer 1, C Behr 1
PMCID: PMC1971697  PMID: 2372491

Abstract

The expression of oestrogen regulated protein, P24, was investigated in 69 breast cancers. At initial evaluation P24 protein was detected significantly more frequently and was present in significantly higher concentration in oestrogen receptor positive than in receptor negative tumours. There was, however, no correlation between P24 staining and progesterone receptor, tumour ploidy or proliferative index. Nineteen patients received a short course of treatment with diethylstilboestrol. Following treatment with oestrogen, P24 staining became positive in 7/13 tumours previously negative for P24, including six tumours which were oestrogen receptor negative. Oestrogen administration also caused an increase of the proliferation index in 12/19 tumours, including 5/7 that were oestrogen receptor positive and 7/12 that were oestrogen receptor negative. In some instances oestrogenic stimulation of proliferation occurred together with increased P24 expression; in other instances proliferation index increased without induction of P24 synthesis. The in vivo effects of oestrogen in clinical breast cancer thus appear to show dissociation between enhancement of protein synthesis and cellular proliferation.

Full text

PDF
886

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. J., Hajj H., Edwards D. P., Bjercke R. J., McGuire W. L. Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Cancer Res. 1983 Sep;43(9):4297–4301. [PubMed] [Google Scholar]
  2. Adams D. J., McGuire W. L. Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors. Cancer Res. 1985 Jun;45(6):2445–2449. [PubMed] [Google Scholar]
  3. Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 1979 May;39(5):1447–1454. [PubMed] [Google Scholar]
  4. Bryant G., Haberern C., Rao C. N., Liotta L. A. Butyrate induced reduction of tumor cell laminin receptors. Cancer Res. 1986 Feb;46(2):807–811. [PubMed] [Google Scholar]
  5. Cant E. M., Horsfall D., Keightley D. D. Value of hormone receptors in the management of breast cancer--I. Advanced breast cancer. Aust N Z J Surg. 1985 Apr;55(2):121–125. doi: 10.1111/j.1445-2197.1985.tb00870.x. [DOI] [PubMed] [Google Scholar]
  6. Ciocca D. R., Adams D. J., Bjercke R. J., Edwards D. P., McGuire W. L. Immunohistochemical detection of an estrogen-regulated protein by monoclonal antibodies. Cancer Res. 1982 Oct;42(10):4256–4258. [PubMed] [Google Scholar]
  7. Ciocca D. R., Adams D. J., Edwards D. P., Bjercke R. J., McGuire W. L. Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res. 1983 Mar;43(3):1204–1210. [PubMed] [Google Scholar]
  8. Ciocca D. R., Adams D. J., Edwards D. P., Bjercke R. J., McGuire W. L. Estrogen-induced 24K protein in MCF-7 breast cancer cells is localized in granules. Breast Cancer Res Treat. 1984;4(4):261–268. doi: 10.1007/BF01806037. [DOI] [PubMed] [Google Scholar]
  9. Ciocca D. R., Asch R. H., Adams D. J., McGuire W. L. Evidence for modulation of a 24K protein in human endometrium during the menstrual cycle. J Clin Endocrinol Metab. 1983 Sep;57(3):496–499. doi: 10.1210/jcem-57-3-496. [DOI] [PubMed] [Google Scholar]
  10. Edwards D. P., Adams D. J., McGuire W. L. Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7). Breast Cancer Res Treat. 1981;1(3):209–223. doi: 10.1007/BF01806261. [DOI] [PubMed] [Google Scholar]
  11. Garcia M., Capony F., Derocq D., Simon D., Pau B., Rochefort H. Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells. Cancer Res. 1985 Feb;45(2):709–716. [PubMed] [Google Scholar]
  12. Garcia M., Salazar-Retana G., Richer G., Domergue J., Capony F., Pujol H., Laffargue F., Pau B., Rochefort H. Immunohistochemical detection of the estrogen-regulated 52,000 mol wt protein in primary breast cancers but not in normal breast and uterus. J Clin Endocrinol Metab. 1984 Sep;59(3):564–566. doi: 10.1210/jcem-59-3-564. [DOI] [PubMed] [Google Scholar]
  13. King W. J., DeSombre E. R., Jensen E. V., Greene G. L. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res. 1985 Jan;45(1):293–304. [PubMed] [Google Scholar]
  14. Logeat F., Vu Hai M. T., Fournier A., Legrain P., Buttin G., Milgrom E. Monoclonal antibodies to rabbit progesterone receptor: crossreaction with other mammalian progesterone receptors. Proc Natl Acad Sci U S A. 1983 Nov;80(21):6456–6459. doi: 10.1073/pnas.80.21.6456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mohla S., Sampson C. C., Khan T., Enterline J. P., Leffall L., Jr, White J. E. Estrogen and progesterone receptors in breast cancer in Black Americans: Correlation of receptor data with tumor differentiation. Cancer. 1982 Aug 1;50(3):552–559. doi: 10.1002/1097-0142(19820801)50:3<552::aid-cncr2820500328>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  16. Nardulli A. M., Greene G. L., O'Malley B. W., Katzenellenbogen B. S. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology. 1988 Mar;122(3):935–944. doi: 10.1210/endo-122-3-935. [DOI] [PubMed] [Google Scholar]
  17. Perrot-Applanat M., Groyer-Picard M. T., Lorenzo F., Jolivet A., Vu Hai M. T., Pallud C., Spyratos F., Milgrom E. Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res. 1987 May 15;47(10):2652–2661. [PubMed] [Google Scholar]
  18. Perrot-Applanat M., Logeat F., Groyer-Picard M. T., Milgrom E. Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology. 1985 Apr;116(4):1473–1484. doi: 10.1210/endo-116-4-1473. [DOI] [PubMed] [Google Scholar]
  19. Rochefort H., Capony F., Augereau P., Cavailles V., Garcia M., Morisset M., Freiss G., Maudelonde T., Vignon F. The estrogen-regulated 52K-cathepsin-D in breast cancer: from biology to clinical applications. Int J Rad Appl Instrum B. 1987;14(4):377–384. doi: 10.1016/0883-2897(87)90015-8. [DOI] [PubMed] [Google Scholar]
  20. Thorpe S. M. Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res. 1987 Dec 15;47(24 Pt 1):6572–6575. [PubMed] [Google Scholar]
  21. Vollenweider-Zerargui L., Barrelet L., Wong Y., Lemarchand-Béraud T., Gómez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer. 1986 Mar 15;57(6):1171–1180. doi: 10.1002/1097-0142(19860315)57:6<1171::aid-cncr2820570618>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES